NCT01316341View on ClinicalTrials.gov

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Empagliflozin in Chinese Female and Male Patients With Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

January 31, 2012

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

BI10773

patient to receive a tablet containing high dose BI10773 p.o. plus one placebo

DRUG

Placebo

patient to receive two placebos

DRUG

Placebo

patient to receive two placebos

DRUG

Placebo

patient to receive two placebos

DRUG

BI10773

patient to receive a tablet containing low dose BI10773 p.o. plus one placebo

Trial Locations (1)

Unknown

1245.44.86001 Boehringer Ingelheim Investigational Site, Beijing

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT01316341 - Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Empagliflozin in Chinese Female and Male Patients With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter